Form 4: PTC Therapeutics CBO Sells Shares Under 10b5-1 Plan

PTC Therapeutics' Chief Business Officer, Eric Pauwels, reported multiple sales of common stock totaling 7,348 shares in early January 2026.

Summary

• Eric Pauwels, Chief Business Officer of PTC Therapeutics, Inc. (PTCT), reported multiple sales of common stock.
• A total of 7,348 shares were sold across several transactions between January 8, 2026, and January 12, 2026.
• The sales were executed at weighted average prices ranging from $76.42 to $78.70 per share.
• Following these transactions, Pauwels beneficially owns 80,141 shares of common stock.
• Most sales were conducted under a Rule 10b5-1 plan adopted on September 15, 2025.
• One transaction, involving 1,454 shares at $76.45, was an automatic 'sell to cover' to satisfy tax withholding obligations related to the vesting of 4,200 Restricted Stock Units (RSUs) from a January 7, 2022 grant.

Sentiment

Score: 5

Explanation: Routine insider sales, primarily under a pre-arranged 10b5-1 plan and for tax obligations, do not strongly indicate positive or negative sentiment regarding the company's future prospects.

Negatives

• Chief Business Officer Eric Pauwels sold a total of 7,348 shares of common stock.
• While largely pre-planned, insider sales can sometimes be perceived negatively by investors, potentially signaling a desire to diversify holdings.

Future Outlook

NA

Management Comments

• This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2025.
• Sales represent shares automatically sold pursuant to irrevocable sell to cover elections entered into upon acceptance of the respective grants to satisfy tax withholding obligations in connection with the vesting of 4,200 RSUs from a January 7, 2022 grant of 16,800 RSUs.

Industry Context

NA

Stakeholder Impact

• Shareholders: Provides transparency regarding insider stock transactions, which can influence investor sentiment.

Key Dates

Recommendation

The reported sales by the Chief Business Officer are largely routine, executed under a pre-arranged 10b5-1 plan or for tax withholding. Such transactions typically do not signal a significant shift in company fundamentals or management's long-term outlook, thus a 'hold' recommendation is appropriate based solely on this filing.

Keywords

PTC Therapeutics, PTCT, Insider Trading, Form 4, Stock Sale, Eric Pauwels, Chief Business Officer, 10b5-1 Plan